Cantech Newsletter: Byron Capital’s Douglas Loe says Neptune Technologies is a BUY

Neptune Technologies & Bioressources
TSX: NTB - NASDAQ: NEPT
Basic Shares: 48.2 million
Fully diluted: 53.9 million
*****************************

Yesterday, Nick Waddell’s widely followed Cantech Letter featured an article on Neptune’s recent announcement on 3rd quarter financial results. The article cites Doug Loe’s latest update on Neptune, which maintains a BUY rating and a price target of $6. Doug Loe is a long time proponent of Neptune and Biotech Analyst at Byron Capital Markets.

“…He (Doug Loe) is impressed with Neptune’s progress. Tuesday’s numbers beat his forecast on revenue, which he thought would be $4.85 million, and on EBITDA, which came in at $1.1 million vs. his $0.985 million forecast. Loe also says he sees several “key events” on the horizon that could add value to Neptune.”

To view the Cantech newsletter article, please click here

To view Doug Loe’s January 17, 2012 updated analyst report on Neptune, please click here..